These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 20097066)

  • 21. Design, synthesis, screening, and molecular modeling study of a new series of ROS1 receptor tyrosine kinase inhibitors.
    El-Deeb IM; Park BS; Jung SJ; Yoo KH; Oh CH; Cho SJ; Han DK; Lee JY; Lee SH
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5622-6. PubMed ID: 19700314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of cyclin-dependent kinase inhibitor, CR229, using structurebased drug screening.
    Kim MK; Min J; Choi BY; Lim H; Cho YH; Lee CH
    J Microbiol Biotechnol; 2007 Oct; 17(10):1712-6. PubMed ID: 18156791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2.
    Paruch K; Dwyer MP; Alvarez C; Brown C; Chan TY; Doll RJ; Keertikar K; Knutson C; McKittrick B; Rivera J; Rossman R; Tucker G; Fischmann TO; Hruza A; Madison V; Nomeir AA; Wang Y; Lees E; Parry D; Sgambellone N; Seghezzi W; Schultz L; Shanahan F; Wiswell D; Xu X; Zhou Q; James RA; Paradkar VM; Park H; Rokosz LR; Stauffer TM; Guzi TJ
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6220-3. PubMed ID: 17904841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
    Sawyer JS; Anderson BD; Beight DW; Campbell RM; Jones ML; Herron DK; Lampe JW; McCowan JR; McMillen WT; Mort N; Parsons S; Smith EC; Vieth M; Weir LC; Yan L; Zhang F; Yingling JM
    J Med Chem; 2003 Sep; 46(19):3953-6. PubMed ID: 12954047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-guided optimization of estrogen receptor binding affinity and antagonist potency of pyrazolopyrimidines with basic side chains.
    Zhou HB; Sheng S; Compton DR; Kim Y; Joachimiak A; Sharma S; Carlson KE; Katzenellenbogen BS; Nettles KW; Greene GL; Katzenellenbogen JA
    J Med Chem; 2007 Jan; 50(2):399-403. PubMed ID: 17228884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors.
    Nien CY; Chen YC; Kuo CC; Hsieh HP; Chang CY; Wu JS; Wu SY; Liou JP; Chang JY
    J Med Chem; 2010 Mar; 53(5):2309-13. PubMed ID: 20148562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis, structure-affinity relationships, and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists.
    Lenzi O; Colotta V; Catarzi D; Varano F; Squarcialupi L; Filacchioni G; Varani K; Vincenzi F; Borea PA; Dal Ben D; Lambertucci C; Cristalli G
    Bioorg Med Chem; 2011 Jun; 19(12):3757-68. PubMed ID: 21616671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
    Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
    Sawyer JS; Beight DW; Britt KS; Anderson BD; Campbell RM; Goodson T; Herron DK; Li HY; McMillen WT; Mort N; Parsons S; Smith EC; Wagner JR; Yan L; Zhang F; Yingling JM
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3581-4. PubMed ID: 15177479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
    Zhu GD; Gandhi VB; Gong J; Thomas S; Woods KW; Song X; Li T; Diebold RB; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Bouska J; Olson A; Marsh KC; Stoll VS; Mamo M; Polakowski J; Campbell TJ; Martin RL; Gintant GA; Penning TD; Li Q; Rosenberg SH; Giranda VL
    J Med Chem; 2007 Jun; 50(13):2990-3003. PubMed ID: 17523610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.
    Lin R; Connolly PJ; Lu Y; Chiu G; Li S; Yu Y; Huang S; Li X; Emanuel SL; Middleton SA; Gruninger RH; Adams M; Fuentes-Pesquera AR; Greenberger LM
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4297-302. PubMed ID: 17532631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting kinase selectivity profiles using Free-Wilson QSAR analysis.
    Sciabola S; Stanton RV; Wittkopp S; Wildman S; Moshinsky D; Potluri S; Xi H
    J Chem Inf Model; 2008 Sep; 48(9):1851-67. PubMed ID: 18717582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor.
    Pawar VG; Sos ML; Rode HB; Rabiller M; Heynck S; van Otterlo WA; Thomas RK; Rauh D
    J Med Chem; 2010 Apr; 53(7):2892-901. PubMed ID: 20222733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines.
    Li HY; Wang Y; Yan L; Campbell RM; Anderson BD; Wagner JR; Yingling JM
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3585-8. PubMed ID: 15177480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and synthesis of novel dihydroquinoline-3-carboxylic acids as HIV-1 integrase inhibitors.
    Sechi M; Rizzi G; Bacchi A; Carcelli M; Rogolino D; Pala N; Sanchez TW; Taheri L; Dayam R; Neamati N
    Bioorg Med Chem; 2009 Apr; 17(7):2925-35. PubMed ID: 19026554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.
    Berger DM; Torres N; Dutia M; Powell D; Ciszewski G; Gopalsamy A; Levin JI; Kim KH; Xu W; Wilhelm J; Hu Y; Collins K; Feldberg L; Kim S; Frommer E; Wojciechowicz D; Mallon R
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6519-23. PubMed ID: 19864136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors.
    Cheung KM; Matthews TP; James K; Rowlands MG; Boxall KJ; Sharp SY; Maloney A; Roe SM; Prodromou C; Pearl LH; Aherne GW; McDonald E; Workman P
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3338-43. PubMed ID: 15955698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and evaluation of thiazepines as interleukin-1beta converting enzyme (ICE) inhibitors.
    Ellis CD; Oppong KA; Laufersweiler MC; O'Neil SV; Soper DL; Wang Y; Wos JA; Fancher AN; Lu W; Suchanek MK; Wang RL; De B; Demuth TP
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4728-32. PubMed ID: 16870441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis of novel anilinoquinolines as c-fms inhibitors.
    Smalley TL; Chamberlain SD; Mills WY; Musso DL; Randhawa SA; Ray JA; Samano V; Frick L
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6257-60. PubMed ID: 17870531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors.
    Gellibert F; Woolven J; Fouchet MH; Mathews N; Goodland H; Lovegrove V; Laroze A; Nguyen VL; Sautet S; Wang R; Janson C; Smith W; Krysa G; Boullay V; De Gouville AC; Huet S; Hartley D
    J Med Chem; 2004 Aug; 47(18):4494-506. PubMed ID: 15317461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.